UBS analyst Trung Huynh lowered the firm’s price target on Eli Lilly (LLY) to $1,050 from $1,100 and keeps a Buy rating on the shares. UBS thinks the selloff is overdone in light of robust GLP franchise sales.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Positive Outlook for Eli Lilly & Co. Despite Competitive Challenges
- Eli Lilly selloff on CVS Wegovy news overdone, says JPMorgan
- Eli Lilly & Co: Strong Market Position and Growth Potential Amid Competitive Pressures
- Eli Lilly Reports Strong Q1 2025 Growth
- Eli Lilly’s Earnings Call: Strong Growth Amid Challenges